Most physicians believe they practiced personalized medicine prior to the genomics era that followed the sequencing of the human genome. The focus of Personalized Medicine has been primarily genomic medicine, wherein it is hoped that the nucleotide dissimilarities among different individuals would provide clinicians with more precise understanding of physiology, more refined diagnoses, better disease risk assessment, earlier detection and monitoring, and tailored treatments to the individual patient.
nucleotide variants (SNVs) that would tag common variants throughout the genome.
This enabled genome-wide association studies (GWAS) for discovery of loci associated with clinical phenotypes. Advances in next generation sequencing (NGS) have reduced the cost and time required for whole exome sequencing (WES) or whole genome sequencing (WGS) and we are continually improving our capacity for handling the storage, transfer and analyses of huge amounts of sequence data. For these reasons, we are entering the window of time where WES and WGS may transition from a basic research tool to an accepted clinical assay.
These days, the term "actionable" is most often used in cancer genomics.
Actionable refers to the ability of the lab information to enable management decisions.
This issue becomes a major challenge for WES or WGS, where many thousands of DNA variants will be identified, most of which do not contribute to the disease being evaluated. Despite this challenge, there are a number of well-publicized examples of how WGS has led to effective treatments of diseases with poor prognoses by providing data on the responsible gene and allowing targeted therapy that would not have otherwise been utilized (Jacobs et al. 20 and http://www.nytimes.com/2012/07/08/health/in-gene-sequencing-treatment-for-leukemiaglimpses-of-the-future.html). These cases illustrate the best possible outcome of "actionable" findings using WES or WGS.
But beyond management decisions, we believe establishing a molecular etiology can also be a valuable actionable outcome of NGS (or any laboratory test). This may be especially true for rare complex pediatric cases of unknown etiology, which currently often involve great financial and emotional expense for families. WGS has been successful for up to half of such patients, 20 and is arguably cost-effective if instituted early in the work-up. Some insurance companies are willing to pay the sequencing For personal use only. on October 31, 2017. by guest www.bloodjournal.org From costs in these settings. Furthermore, establishing a diagnosis can affect a management plan, even if it does not lead to a specific drug therapy.
Despite these incredible advances, numerous complex issues need to be addressed before WES and WGS can and should become a common component of patient evaluation.
21-25

Different genomics in thrombosis versus cancer and malignant hematology
A fundamental difference between the genomics of thrombosis and malignancy is that somatic cancerous cells acquire an altered genome with driver mutations that differs from the germ line genome. Identification of these causative mutations in cancer cells may permit utilization of therapies targeting specific genes or gene products that have a large effect on the phenotype (cancer). On the other hand, the genetic contribution to thrombosis (or other non-malignant disorders) is housed in the germ line genome.
Unlike acquired driver mutations in malignancy, even the most penetrable thrombophilias (like antithrombin deficiency) are not so harmful as to prevent a healthy life until adulthood in subjects with haploinsufficiency. For adult complex multifactorial diseases like VTE and atherothrombosis, innumerable low effect genes are likely to explain only a fraction of the phenotypic variance. 9, 26, 27 Current personalized medicine in thrombosis diagnosis and management
Venous thrombotic disorders
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Genetic and acquired factors play a role in the pathogenesis of VTE. The current management of VTE is primarily determined by the presence or absence of a significant provoking and modifiable factor. Currently, the data support at least 3 months of anticoagulation therapy for patients with provoked VTE. However, common practice may use up to 6 months (or longer) anticoagulation where the treating physician personalizes treatment based on clinical factors she/he deems important, such as location/severity of the thrombosis, on-going inflammation, etc.
The situation with unprovoked VTE is different and typically involves long-term anticoagulation. When there is a question regarding the feasibility of long-term anticoagulation, patient characteristics (sex, age and BMI), nature of the initial VTE (distal DVT vs proximal, DVT vs PE) and assays of global hemostasis like D-dimer are used for recurrence risk assessment and personalizing therapy. The above-mentioned variables have been incorporated into recurrence risk assessment models like the Rodgers model (MEN continue HER DOO2), Vienna model or DASH score (D-dimer, age, sex and hormone use) commonly used in practice. [28] [29] [30] Considerably more refinement and validation is needed before such genetic testing would be applied to treatment approaches.
Arterial thrombotic disorders
It is beyond the scope of this Perspective to discuss the enormous literature relevant to the genetics and genomics of atherothrombotic disease. For adult Hematologists, the relevance largely pertains to the central role of platelets in arterial thrombus formation and anti-platelet therapies, 56,57 which will be the focus of this section.
Homocystinuria is a genetic disorder associated with arterial thrombosis typically diagnosed in childhood.
Platelet hyperreactivity plays a significant role in the pathogenesis of initial and recurrent arterial thrombosis. 
A history and physical exam initiates the genomic evaluation and provides value
Genetic testing will be of little value for most patients with acquired thrombosis.
However, family history of VTE is a strong risk factor for VTE even after adjusting for major thrombophilic defects and common VTE-associated SNVs.
68 Thus, a personal and family medical history remains the cornerstone for evaluating thrombosis etiology.
Unfortunately, obtaining an accurate family health history is often challenging given the time constraints on the medical personnel and limited resources. Online and patient facing family health history collection tools can be used to help obtain accurate family health histories.
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From the molecular genetic point of view, there is ample evidence supporting relationships between genomics/gene expression and simple demographic information obtained via a thorough medical history and physical examination. For example, selected genomic markers strongly correlate with self-identified race and ancient geographical ancestry. 70, 71 Many coding and non-coding RNAs are significantly differentially expressed by age and gender. 72 Where a person lives accounts for nearly 25% of the variation in a substantial portion (one-third) of their cellular transcripts. 73 For the foreseeable future, patient diagnosis and management will be based on these traditional mechanisms of patient evaluation (history, physical and lab), rather than the patient's genomic sequence. And the former is more efficiently and cheaply obtained.
Consider, for example, the value of the 4Ts score for the diagnosis of heparin-induced thrombocytopenia and thrombosis. Financing healthcare has begun transitioning away from fee-for-service to valuebased medicine in the U.S. Although many different algorithms have been implemented, the basic equation of value-based medicine is patient outcomes divided by the costs for delivering those outcomes. For patients this means persistent effective care at reasonable cost. We believe a good medical history and physical examination can reduce unnecessary and expensive lab testing, imaging and consultations, and thereby enhance the value of care.
Future opportunities for personalized medicine for thrombosis
Newer tests of global hemostasis, such as in vitro thrombin generation, may have a role in personalizing VTE management.
To capitalize on the power of NGS, large populations of patients will be required for novel thrombosis gene discovery and novel, actionable pharmacogenetic interactions. First generation genetic risk scores and "thrombo-chips" may benefit from additional markers identified by NGS, and will need further evaluation and confirmation before they can be utilized in clinical practice.
Because of the central role of platelets in atherothrombotic disease, there has been an increasing number of platelet RNA association studies, primarily in cardiovascular disease. [75] [76] [77] Transcriptome-wide association studies also provide an unbiased approach to novel functional gene discovery; e.g., miRNAs associated with myocardial infarction. 78 Relevant to hemostasis/thrombosis, RNA is most easily available from platelets, which reflects the megakaryocyte transcriptome. 79 Serum and plasma can serve as a source for RNAs from platelets, liver and endothelial cells, but it 1 7
will be critical to consider confounding demographic variables and co-morbid disease known to affect blood RNA levels.
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The potential of pharmacogenetics to impact on Personalized Medicine in thrombosis will require that clinical trials of antithrombotic agents include both genomic data as well as other measure of factors that affect the response to therapy, such as accurate clinical, environmental, social, dietary, etc. information. 80 Gene-gene, geneenvironment and pharmacogenetic interactions are largely unexplored in thrombotic disease, and large sample sizes will be needed to tap this potential.
Because PAR4 is the only functioning receptor for thrombin in the presence of vorapaxar, it will be of interest to understand the pharmacogenetic effect of the PAR4 Ala120Thr variant in patients using any PAR1 or PAR4 blocker, and clinical trials are needed that consider the rs773902 genotype. Such pharmacogenetic data may provide a rational basis for decisions about benefit or harm of novel anti-platelet agents.
It is increasingly likely that Hematologists will be faced with patients who have had their genomes sequenced and who ask about variants that may be associated with thrombosis or anti-thrombotic utility. The identification of rare, family-specific variants will require functional and clinical assessment for effect size on thrombosis risk.
Because the number of such variants may be large, recommendations from expert subcommittees of international societies could promote personalized management.
The novel genetic markers discovered and validated in previously mentioned studies may have a higher impact in personalizing management as genome sequencing for all individuals becomes routine in the future due to rapidly reducing cost. 
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